With the impending legalization of cannabis, Canadian pet owners may soon have the opportunity to consider using medicinal cannabis for their pets. Similar to the human medicinal market, high-quality, pharmaceutical-grade cannabis products can be an option integrated into veterinary practice to support the overall health and well-being of pets. While cannabis use in the veterinary space is not currently approved by Health Canada, there is a demand from pet owners and veterinarians to accelerate clinical research and development of cannabis-based treatments.
Cannabis contains hundreds of active compounds (i.e., cannabinoids and terpenes) that provide a wide range of therapeutic benefits. Tetrahydrocannabidiol (THC) and cannabidiol (CBD) are two of the most well-known phytocannabinoids. Animals have an endocannabinoid system, just like humans, that responds to exogenous cannabinoids. Much like humans, cannabis can have therapeutic benefits for companion animals.
In human medicine, cannabis is used to treat a variety of conditions, including chronic pain, anxiety and other behavioral concerns, seizures, general inflammation, sleep quality, gastrointestinal conditions, cancer and skin disorders. We expect cannabis to be helpful in treating a similar range of conditions in animals.
Dr. Ian Sandler, CEO of Grey Wolf Animal Health, will be answering frequently asked questions from veterinarians about the future of cannabis in companion animals at the upcoming ve+ summit on September 15th through his talk "A Practitioners Guide to Veterinary Medicine in Canada".
Grey Wolf Animal Health is committed to supporting advocacy, providing education, advancing clinical evidence and developing a portfolio of ground-breaking pharmaceutical and cannabis products to support the well-being companion animals.
The ve+ summit will examine and evaluate some of veterinary medicine’s newest technologies. Buy your ticket today!